[go: up one dir, main page]

LT2593463T - Rifaksimino kompozicijos ir jų panaudojimas - Google Patents

Rifaksimino kompozicijos ir jų panaudojimas

Info

Publication number
LT2593463T
LT2593463T LTEP11807418.6T LT11807418T LT2593463T LT 2593463 T LT2593463 T LT 2593463T LT 11807418 T LT11807418 T LT 11807418T LT 2593463 T LT2593463 T LT 2593463T
Authority
LT
Lithuania
Prior art keywords
rifaximin compositions
rifaximin
compositions
Prior art date
Application number
LTEP11807418.6T
Other languages
English (en)
Inventor
Jon Selbo
Jing TENG
Mohammed Kabir
Pam Golden
Original Assignee
Salix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals, Inc. filed Critical Salix Pharmaceuticals, Inc.
Publication of LT2593463T publication Critical patent/LT2593463T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LTEP11807418.6T 2010-07-12 2011-07-12 Rifaksimino kompozicijos ir jų panaudojimas LT2593463T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36360910P 2010-07-12 2010-07-12
US41905610P 2010-12-02 2010-12-02
PCT/US2011/043769 WO2012009388A1 (en) 2010-07-12 2011-07-12 Formulations of rifaximin and uses thereof

Publications (1)

Publication Number Publication Date
LT2593463T true LT2593463T (lt) 2020-08-25

Family

ID=45469785

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11807418.6T LT2593463T (lt) 2010-07-12 2011-07-12 Rifaksimino kompozicijos ir jų panaudojimas

Country Status (28)

Country Link
US (4) US20120077835A1 (lt)
EP (2) EP3750526A1 (lt)
JP (1) JP5943915B2 (lt)
KR (1) KR101887004B1 (lt)
CN (1) CN103228662B (lt)
AU (1) AU2011279261B2 (lt)
BR (1) BR112013000802B1 (lt)
CA (1) CA2804635C (lt)
CR (1) CR20130033A (lt)
DK (1) DK2593463T3 (lt)
EA (1) EA033370B1 (lt)
ES (1) ES2801678T3 (lt)
GE (2) GEAP202112996A (lt)
HU (1) HUE049986T2 (lt)
IL (1) IL223725B (lt)
LT (1) LT2593463T (lt)
MX (1) MX345697B (lt)
MY (1) MY165086A (lt)
NZ (1) NZ605232A (lt)
PH (1) PH12013500082B1 (lt)
PL (1) PL2593463T3 (lt)
PT (1) PT2593463T (lt)
SG (2) SG10201505484RA (lt)
SI (1) SI2593463T1 (lt)
SM (1) SMT202000390T1 (lt)
TN (1) TN2012000611A1 (lt)
WO (2) WO2012009387A1 (lt)
ZA (1) ZA201300193B (lt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) * 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
HK1204614A1 (en) 2012-01-25 2015-11-27 Salix Pharmaceuticals, Ltd. Rifaximin derivative and uses thereof
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2757135B1 (en) 2013-01-18 2017-11-29 3M Innovative Properties Company Method of bonding parts to a vehicle by an acrylic foam tape
WO2015069305A1 (en) * 2013-11-08 2015-05-14 Tyrx, Inc. Antimicrobial compositions and methods for preventing infection in surgical incision sites
JP6693946B2 (ja) 2014-05-04 2020-05-13 サリックス ファーマスーティカルズ,インコーポレーテッド Ibs微生物叢及びその使用
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
JP7024248B2 (ja) * 2016-09-01 2022-02-24 大正製薬株式会社 固形製剤
CA3038312A1 (en) * 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
WO2019022784A1 (en) * 2017-07-24 2019-01-31 Acryspharm Llc PHARMACEUTICAL COMPOSITIONS WITH HIGH MEDICATION CHARGE
CN109453166B (zh) * 2018-10-16 2021-03-12 丹诺医药(苏州)有限公司 一种利福霉素-喹嗪酮偶联分子的固体分散体及其应用
CN109453165B (zh) * 2018-10-16 2021-02-05 丹诺医药(苏州)有限公司 一种利福霉素-硝基咪唑偶联分子的固体分散体及其应用
WO2020198136A1 (en) * 2019-03-22 2020-10-01 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease
CN114401721A (zh) 2019-09-24 2022-04-26 博士医疗爱尔兰有限公司 利福昔明液体制剂
AU2021241001A1 (en) * 2020-03-24 2022-10-20 Bausch Health Ireland Limited Solid dispersions of rifaximin for the treatment of Overt Hepatic Encephalopathy
WO2021209459A1 (en) * 2020-04-13 2021-10-21 Bausch Health Ireland Limited Methods of using solid dispersions of rifaximin for the treatment of sickle cell disease
AU2021298178A1 (en) 2020-06-26 2023-02-02 Bausch Health Ireland Limited Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease
CN114366717B (zh) * 2022-01-11 2023-06-09 四川农业大学 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用
WO2025151876A1 (en) * 2024-01-11 2025-07-17 Minneamrita Therapeutics Llc Triptolide formulations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1320176B1 (it) 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
CA2448864C (en) * 2001-06-22 2008-04-22 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
PL2011486T5 (pl) * 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
KR100903618B1 (ko) * 2007-10-30 2009-06-18 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
CN102015725B (zh) * 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP3563850A1 (en) * 2008-02-26 2019-11-06 Salix Pharmaceuticals, Ltd. Methods for treating bowel diseases
EP2105130A1 (de) * 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
CA2745980C (en) * 2008-12-10 2017-10-31 Cipla Limited Rifaximin complexes
UA110199C2 (xx) * 2009-10-27 2015-12-10 Lupin Ltd Тверда дисперсія рифаксиміну
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
PH12012501784A1 (en) * 2010-03-10 2022-10-05 Abbvie Bahamas Ltd Solid compositions

Also Published As

Publication number Publication date
SG10201505484RA (en) 2015-09-29
MX2013000522A (es) 2013-05-01
CR20130033A (es) 2013-04-29
US20120077835A1 (en) 2012-03-29
KR101887004B1 (ko) 2018-08-09
EP2593463A4 (en) 2014-04-23
MY165086A (en) 2018-02-28
AU2011279261B2 (en) 2016-03-31
US20200397904A1 (en) 2020-12-24
US9737610B2 (en) 2017-08-22
PT2593463T (pt) 2020-09-17
BR112013000802A2 (pt) 2016-05-24
WO2012009388A1 (en) 2012-01-19
CN103228662B (zh) 2016-08-10
JP2013532633A (ja) 2013-08-19
GEAP202112996A (en) 2021-09-10
EP3750526A1 (en) 2020-12-16
CA2804635C (en) 2019-09-10
IL223725B (en) 2020-03-31
SMT202000390T1 (it) 2020-09-10
HUE049986T2 (hu) 2020-11-30
SG186981A1 (en) 2013-02-28
PH12013500082A1 (en) 2013-03-11
PL2593463T3 (pl) 2020-11-02
WO2012009387A1 (en) 2012-01-19
SI2593463T1 (sl) 2020-10-30
JP5943915B2 (ja) 2016-07-05
US20170333562A1 (en) 2017-11-23
DK2593463T3 (da) 2020-08-10
PH12013500082B1 (en) 2019-06-28
MX345697B (es) 2017-02-13
NZ605232A (en) 2015-09-25
EP2593463A1 (en) 2013-05-22
ZA201300193B (en) 2019-07-31
KR20130098300A (ko) 2013-09-04
TN2012000611A1 (en) 2014-04-01
CN103228662A (zh) 2013-07-31
ES2801678T3 (es) 2021-01-12
US20150133482A1 (en) 2015-05-14
EP2593463B1 (en) 2020-05-06
BR112013000802B1 (pt) 2021-08-31
GEP20227342B (en) 2022-01-25
CA2804635A1 (en) 2012-01-19
EA201370018A1 (ru) 2013-09-30
AU2011279261A1 (en) 2013-01-17
EA033370B1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
LT2593463T (lt) Rifaksimino kompozicijos ir jų panaudojimas
LT3202460T (lt) Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
LT2605789T (lt) Modifikuoti relaksino polipeptidai ir jų panaudojimas
LT3495392T (lt) Anti-cgrp kompozicijos ir jų panaudojimas
DK2640893T4 (da) Sammensætninger
LT3246021T (lt) Apiksabano kompozicijos
BR112012031667A2 (pt) composição
DK2542189T3 (da) Håndprotese
PL2611310T3 (pl) Formulacja antybakteryjna
FR2968591B3 (fr) Accessoire multi-lames
LT2552434T (lt) Peptidai ir jų naudojimas
LT2704703T (lt) Transderminės ibuprofeno kompozicijos ir jų naudojimo būdai
SMT201600458B (it) Composizioni comprendenti buprenorfina
LT2533761T (lt) Aerozolių gamybos būdai ir kompozicijos
BR112012032683A2 (pt) composição
LT2523678T (lt) Wnt antagonistai ir gydymo būdai
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
EP2552212A4 (en) IMPROVED FORMULATION
EP2636704A4 (en) FILM FORMING COMPOSITION
BR112013009627A2 (pt) composições de tinta
EP2531023A4 (en) IMPROVED FORMULATION
BR112012032980A2 (pt) composição
EP2628769A4 (en) FILM FORMING COMPOSITION
PL2635269T3 (pl) Kompozycja złożona
EP2548928A4 (en) PIGMENT COMPOSITION